<DOC>
	<DOCNO>NCT02953418</DOCNO>
	<brief_summary>Multicenter , prospective cohort clinical trial great China</brief_summary>
	<brief_title>RFA Flat Type High-grade Medium-grade Intraepithelial Squamous Neoplasia</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>1 . Patient 1885 year age 2 . Patient evidence ESCN , within last 3 month , patient demonstrate new diagnosis reconfirm diagnosis squamous MGIN HGIN esophagus 3 . On endoscopic examination , subject least one USL measure least 3 cm least one dimension great ¼ esophageal circumference MGIN HGIN biopsy , confirmed central pathologist 4 . All lesion completely flat ( type 0IIb ) WLE Lugol 's chromoendoscopy 5 . The maximum allowable linear length `` USLbearing esophagus '' 12 cm 6 . Baseline endoscopic ultrasound ( EUS ) ( applicable ) show exclusionary finding trial 7 . Computed tomography ( CT ) scan chest upper third abdomen ( applicable ) show exclusionary finding trial 8 . Based judgment study endoscopist , patient eligible treatment followup endoscopy biopsy require protocol 9 . The subject willing provide write , inform consent participate clinical study understand responsibility trial participation 1 . Patient esophageal squamous cell carcinoma ( ESCC ) 2 . Any nonflat ( Paris type 0I , 0IIa , 0IIc , 0III ) abnormality anywhere esophagus 3 . Any USL MGIN bad biopsy outside treatment area 4 . Esophageal stricture prevent passage therapeutic endoscope 5 . Any prior endoscopic mucosal resection ( EMR ) endoscopic submucosal dissection ( ESD ) 6 . Any esophageal dilation past 12 month 7 . Any history nonsquamous cell cancer esophagus , history squamous cell cancer esophagus ( stage ) 8 . Any previous ablative therapy within esophagus ( photodynamic therapy , multipolar electrical coagulation , argon plasma coagulation , laser treatment , ) radiation therapy esophagus . 9 . Previous esophageal surgery , except fundoplication without complication ( i.e. , slippage , dysphagia , etc . ) 10 . Evidence esophageal varix detect within last 6 month initial RFA procedure 11 . Patient active reflux esophagitis grade C D. 12 . Evidence eosinophilic esophagitis endoscopy and/or histology 13 . Inner diameter esophagus measure less 18mm 14 . Report uncontrolled coagulopathy international normalize ratio ( INR ) &gt; 2 platelet count &lt; 75,000 platelet per µL ( note : complete blood count require subject study ) 15 . Patient use aspirin , clopidogrel , nonsteroidal antiinflammatory drug discontinue 7 day therapeutic session 16 . Patient implantable pacing device ( example : automate implantable cardioverter defibrillator , neurostimulator , cardiac pacemaker ) receive clearance enrollment study specialist responsible pacing device 17 . Patient life expectancy le 2 year 18 . Patient suffers psychiatric illness and/or know history unresolved drug alcohol dependency would limit ability comprehend follow instruction relate informed consent , post treatment instruction , followup guideline 19 . Patient consider part vulnerable population ( e.g . prisoner without sufficient mental capacity ) 20 . The subject participate investigational drug device research study within 30 day enrollment would interfere study 21 . Patient pregnant plan become pregnant ensue 12 month ( confirmation nonpregnant status woman childbearing age ability require urine blood test eligible )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>